Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05743270
Other study ID # RP3-002
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date January 30, 2024
Est. completion date June 1, 2026

Study information

Verified date December 2023
Source Replimune Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2, multicenter, open-label, 2-cohort (Locoregionally Advanced Cohort or Recurrent/Metastatic Cohort) study evaluating RP3 in combination with concurrent chemoradiation therapy (CCRT) followed by nivolumab (for the LA Cohort) or combined with chemotherapy and nivolumab (for the R/M Cohort) in patients with advanced, inoperable squamous cell carcinomas of the head and neck (SCCHN), including of the oral cavity, oropharynx, hypopharynx, larynx, or unknown primary.


Description:

RP3 is a genetically modified herpes simplex type 1 virus (HSV-1) that expresses exogenous genes (anti-CTLA-4 antibody, CD40 ligand and h4-1BBL) designed to directly kill tumor cells and generate a systemic anti-tumor immune response


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 1, 2026
Est. primary completion date March 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histological diagnosis of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx or of a lymph node(s) anywhere in levels I to V of the neck that has been excluded clinically from association with cancer from a non-head and neck site - All patients Must be willing to consent to provide archival or fresh tumor biopsy samples obtained within 60 days prior to initiation of study treatment. Patients must also consent to provide on-treatment biopsies as per protocol. - At least 1 measurable lesion of = 1 cm in longest diameter (or shortest diameter for lymph nodes), in accordance with RECIST. - At least injectable tumors of at least 1 cm in aggregate overall longest diameter. - Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 -1. Locally Advanced Cohort Only • patients must not be amenable to surgery with curative intent Previously untreated high-risk disease meeting at least 1 of the following criteria: - Oral cavity, hypopharynx, larynx, oropharynx (p16 negative): Stage III/ IV Note: Cancers of the oral cavity, hypopharynx, and larynx are eligible irrespective of p16 status. These patients will not be stratified by p16 status. - For p16 positive oropharynx cancers, patients must have either - T3 and/or N2 or greater disease with active smoking and/or greater than 20 pack year smoking history OR - T4 and/or N3 disease irrespective of tobacco use - SCCHN of unknown primary Stage III/IV irrespective of p16 status or smoking status. - Eligible for definitive CCRT with curative intent. R/M Cohort Only - Has recurrent or metastatic SCCHN eligible for first line systemic therapy for R/M disease. - Has a PD-L1 CPS <20. Exclusion Criteria: - Primary tumors of nasopharynx, paranasal sinuses, nasal passages, salivary gland, thyroid or parathyroid gland, or skin. - Tumors with histopathology indicating the tumor has sarcomatous, sarcomatoid, verrucous, mixed, undifferentiated, or otherwise nonsquamous components. - Has an airway that is not deemed safe and stable on flexible fiberoptic laryngoscopy (FFL) performed by a head & neck cancer specialist within 7 days of first RP3 injection. - Has a baseline serum albumin (at Screening) <2.5 g/dL and/or evidence of cachexia or muscle wasting during physical exam at Screening. - Known acute or chronic hepatitis B or acute or chronic hepatitis C - Systemic infection requiring intravenous (IV) antibiotics - Active significant herpetic infections or prior complications of HSV-1 infection (eg, herpetic keratitis or encephalitis) - History of interstitial lung disease. - History of (noninfectious) pneumonitis that required steroids or has current pneumonitis. - Patients who require intermittent or chronic use of systemic (oral or IV) antivirals with known antiherpetic activity (eg, acyclovir). - Administration of live vaccine within 28 days prior to the first dose of study treatment. - History of allergy or sensitivity to study drug components or prior monoclonal antibody treatment. - History of life-threatening toxicity related to prior immune treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways - History of viral infections according to the protocol - Treatment with botanical preparations within 2 weeks prior to treatment. - Major surgery = 2 weeks prior to starting study treatment. LA Cohort only - Has received prior radiotherapy for SCCHN. - Has received any prior systemic therapy for SCCHN. R/M cohort only - Is eligible for radiation and/or surgery with curative intent. - Has received systemic therapy for recurrence or new (ie, not present at the time of initial diagnosis) metastases of SCCHN. - Received a paclitaxel-containing regimen as part of frontline treatment (prior to R/M disease) with a documented best response of stable disease (SD) or PD (patients who achieved a partial response [PR] or CR are eligible). - Received a carboplatin-containing regimen as part of frontline treatment (prior to R/M disease) with a documented best response of SD or PD (patients who achieved PR or CR are eligible). - Patients with known intolerance to carbo-platinum and/or paclitaxel, including hypersensitivity to Cremophor® EL (polyoxyethylated castor oil). - Previously received multiple courses of irradiation to the same anatomic site unless such patient has nondoubly-irradiated, measurable, injectable lesions, which are the only lesions to be used as target lesions (for nodal disease, only lesions in nodal basins that have been previously irradiated just once or not irradiated at all may be injected and/or used as target lesions). Note: Other protocol defined inclusion/exclusion criteria apply for each cohort

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
RP3
Genetically modified herpes simplex type 1 virus
Other:
CCRT(concurrent chemoradiation therapy)
CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
carboplatin and paclitaxel
chemotherapeutic agents
Biological:
nivolumab
anti-PD1 monoclonal antibody

Locations

Country Name City State
Czechia University Hospital Olomouc Olomouc
Czechia Fakultni Thomayerova Nemocnice Prague
Czechia FN Kralovske Vinohrady Praha
France Centre Georges Francois Leclerc, Department of Oncology Dijon
France Centre Leon Berard Lyon
France Assistance Publique Hopitaux De Marseille Marseille
France CHU Nimes, Instiut de Cancerologie du Gard, Medical Oncology Nîmes
France Institut Gustave Roussy Paris Villejuif
Germany Charite University Hospital of Berlin, Comprehensive Cancer Center Berlin
Germany Universitatsklinik Jena Klinik und Poliklinik fur Hals-, Nasen - und Ohrenheilkunde Jena
Germany University Hospital Leipzig Clinic and Polyclinic for otorhinolaryngology Leipzig
Germany LMU Klinikum, Medizinische Klinik und Poliklinikum III Munich
Germany Universitatsklinikum Ulm Ulm
Greece University General Hospital Attikon Chaïdári
Greece Agios Lukas Hospital Thessaloníki
Poland Szpital Specjalistyczny im Ludwika Rydygiera w Krakowie sp z oo, Department of Clinical Oncology Kraków
Spain Vall d'Hebron University Hospital, Vall d' Hebron Institute of Oncology (VHIO) Barcelona
Spain Hospital Universitario HM Sanchinarro Madrid
Spain La Paz Univeristy Hospital, Universidad Autonoma de Madrid Madrid
Spain Clinica Universitaria de Navarra Pamplona
Spain Fundacion Instituto Valenciano de Oncologia Valencia
United Kingdom The Royal Marsden NHS Foundation Trust London
United States University of Cincinnati Medical Center Cincinnati Ohio
United States Cleveland Clinic Cleveland Ohio
United States University of Iowa Hospitals and Clinics Iowa City Iowa
United States University of California San Diego, UCSD La Jolla California
United States UCLA Medicine Division of Hematology-Oncology Los Angeles California
United States USC Norris Comprehensive Cancer Center Los Angeles California
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Sarah Cannon Research Institute Nashville Tennessee
United States Thomas Jefferson University City Center and Abington Philadelphia Pennsylvania
United States University of Pittsburgh Medical Center, UPMC Pittsburgh Pennsylvania
United States University of Washington / Fred Hutchinson Cancer Center Seattle Washington
United States Jefferson Health Abington Asplunhd Cancer Pavillion Willow Grove Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Replimune Inc. Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Czechia,  France,  Germany,  Greece,  Poland,  Spain,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary LA Cohort: Progression-free Survival Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first From Day 1 to documented progression of disease (up to 3 years)
Primary R/M Cohort: Objective Response Rate Percentage of subjects achieving objective response (complete response + partial response) From Day 1 to documented progression of disease (up to 3 years)
Secondary LA Cohort: Progression-free Survival Rates at 6 and 12 Months Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first From Day 1 to documented progression of disease (up to 12 months)
Secondary LA Cohort: Overall Survival Rate at 1, 2, and 3 Years Overall survival is defined as the time from the first day of study treatment to the date of death by any cause From Day 1 to date of death by any cause (up to 3 years)
Secondary LA Cohort: Overall Response Rate and Metabolic Overall Response Rate Overall Response Rate is the percentage of subjects achieving objective response (complete response + partial response) Metabolic overall response rate is the percentage of subjects achieving objective metabolic response (complete metabolic response + partial metabolic response) From Day 1 to documented progression of disease (up to 3 years)
Secondary LA Cohort: Complete Response Rate and Metabolic Complete Response Rate at 5-and 8-months Following of Initiation of Radiation Following of Initiation of Radiation Complete response rate is the percentage of subjects achieving complete response
Metabolic complete response rate is the percentage of subjects achieving metabolic complete response
From Day 1 to documented progression of disease (up to 8Months Following of Initiation of Radiation)
Secondary LA Cohort: Proportion of Patients Achieving No-Evidence-of-Disease Status by Any Means (Including Salvage Surgery) No-evidence-of-disease is defined as no evidence of malignancy at any site From Day 1 to end of study (up to 3 years)
Secondary LA Cohort: Cumulative Incidence of Locoregional Failure Locoregional Failure is defined as tumor growth or disease infiltration or spread at the primary tumor location and/or at anatomic areas of local and/or regional disease. From Day 1 to end of study (up to 3 years)
Secondary LA Cohort: Cumulative Incidence of Distant Metastatic Failure Distant metastatic failure is defined as growth of metastases or new appearance of metastases in lung, bone, liver, other distant organs, and/or distant lymph node stations. From Day 1 to end of study (up to 3 years)
Secondary LA Cohort: Duration of Clinical Benefit Duration of clinical benefit is defined as the time from the first day of study treatment to last progression of disease, which was subsequently confirmed or with no further follow-up for response, or death due to any cause, whichever occurs first, for subjects who achieve complete response, partial response, or stable disease From Day 1 to documented progression of disease (up to 3 years)
Secondary LA Cohort: Summary of Patient-Reported Outcomes Measured by FACT-HNSI-22 FACT-HNSI-22 is a Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index which consists of 22 items. Each item is scored in a 5 point Likert-type scale: 0=Not at all, 1=A little bit, 2=Some-what, 3=Quite a bit, and 4=Very much. The higher the score, the worse the patient outcome. From Day 1 to 52 Weeks.
Secondary LA Cohort: Summary of Patient-Reported Outcomes Measured by EQ-5D-5L EQ-5D-5L is a self-assessed, health related, quality of life questionnaire which consists of 2 pages: EQ-5D descriptive system and EQ visual analogue scale (EQ VAS). The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale which is numbered from 0 to 100. 0 means the worst health the patient can imagine. 100 means the best health the patient can imagine. The higher the score, the better the patient outcome. From Day 1 to 52 Weeks
Secondary LA Cohort: Frequency, Nature, and Severity of TEAEs and SAEs Percentage of subjects with TEAEs and SAEs From Screening through 60 days after last dose of RP3, or 100 days after last dose of nivolumab, or 28 days after last dose of either cisplatin, carboplatin, or paclitaxel, whichever occurs last
Secondary R/M Cohort: Progression-free Survival Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first From Day 1 to documented progression of disease (up to 3 years)
Secondary R/M Cohort: Progression-free Survival Rates at 6 and 12 Months Progression-free survival is defined as the time from the first day of study treatment to the date of progression of disease, which was subsequently confirmed, or death by any cause, whichever occurs first From Day 1 to documented progression of disease (up to 12 months)
Secondary R/M Cohort: Overall Survival Rates at 1, 2, and 3 Years Overall survival is defined as the time from the first day of study treatment to the date of death by any cause From Day 1 to date of death by any cause (up to 3 years)
Secondary R/M Cohort: Duration of Response Duration of response is defined as the time from documented response until the date of progression of disease, which was subsequently confirmed or with no further follow-up, or death due to any cause, whichever occurs first From Day 1 to documented progression of disease (up to 3 years)
Secondary R/M Cohort: Duration of Clinical Benefit Duration of clinical benefit is defined as the time from the first day of study treatment to last progression of disease, which was subsequently confirmed or with no further follow-up for response, or death due to any cause, whichever occurs first, for subjects who achieve complete response, partial response, or stable disease From Day 1 to documented progression of disease (up to 3 years)
Secondary R/M Cohort: Complete Response Rate Percentage of subjects achieving a complete response From Day 1 to documented progression of disease (up to 3 years)
Secondary R/M Cohort: Disease Control Rate Percentage of patients achieving complete response, partial response, or stable disease From Day 1 to documented progression of disease (up to 3 years)
Secondary R/M Cohort: Number of Patients Who Undergo Attempted Definitive Resection Number of Patients Who Undergo Attempted Definitive Resection From Day 1 to end of study (up to 3 years)
Secondary R/M Cohort: Frequency, Nature, and Severity of TEAEs and SAEs Percentage of subjects with TEAEs and SAEs From Screening through 60 days after last dose of RP3, or 100 days after last dose of nivolumab, or 28 days after last dose of either cisplatin, carboplatin, or paclitaxel, whichever occurs last
See also
  Status Clinical Trial Phase
Completed NCT04879849 - A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Completed NCT02537223 - Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer Phase 1
Completed NCT00824343 - A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT06022757 - Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) Phase 1/Phase 2
Recruiting NCT05366166 - Pembrolizumab Plus Olaparib in LA-HNSCC Phase 2
Terminated NCT04502888 - Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Phase 1
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Completed NCT04098458 - Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC N/A
Not yet recruiting NCT04528420 - Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer N/A
Active, not recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05061420 - A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) Phase 2
Completed NCT04939480 - Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN Phase 2
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Recruiting NCT04465487 - Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies Phase 1
Not yet recruiting NCT05845307 - Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck Early Phase 1
Active, not recruiting NCT04489888 - A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) Phase 4
Recruiting NCT05544929 - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers Phase 1
Completed NCT04601402 - GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy Phase 1
Completed NCT00756444 - A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck Phase 2